2022-08-292023-08-312023-08-31falseSC742693GLASGOW LIVER CLINIC LTD2024-05-1586220iso4217:GBPxbrli:pureSC7426932022-08-29SC7426932023-08-31SC7426932022-08-292023-08-31SC7426932022-08-28SC7426932022-08-28SC7426932022-08-282022-08-28SC742693bus:SmallEntities2022-08-292023-08-31SC742693bus:AuditExempt-NoAccountantsReport2022-08-292023-08-31SC742693bus:AbridgedAccounts2022-08-292023-08-31SC742693bus:PrivateLimitedCompanyLtd2022-08-292023-08-31SC742693core:WithinOneYear2023-08-31SC742693core:AfterOneYear2023-08-31SC742693core:WithinOneYear2022-08-28SC742693core:AfterOneYear2022-08-28SC742693core:ShareCapital2023-08-31SC742693core:SharePremium2023-08-31SC742693core:RevaluationReserve2023-08-31SC742693core:OtherReservesSubtotal2023-08-31SC742693core:RetainedEarningsAccumulatedLosses2023-08-31SC742693core:ShareCapital2022-08-28SC742693core:SharePremium2022-08-28SC742693core:RevaluationReserve2022-08-28SC742693core:OtherReservesSubtotal2022-08-28SC742693core:RetainedEarningsAccumulatedLosses2022-08-28SC742693core:LandBuildings2023-08-31SC742693core:PlantMachinery2023-08-31SC742693core:Vehicles2023-08-31SC742693core:FurnitureFittings2023-08-31SC742693core:OfficeEquipment2023-08-31SC742693core:NetGoodwill2023-08-31SC742693core:IntangibleAssetsOtherThanGoodwill2023-08-31SC742693core:ListedExchangeTraded2023-08-31SC742693core:UnlistedNon-exchangeTraded2023-08-31SC742693core:LandBuildings2022-08-28SC742693core:PlantMachinery2022-08-28SC742693core:Vehicles2022-08-28SC742693core:FurnitureFittings2022-08-28SC742693core:OfficeEquipment2022-08-28SC742693core:NetGoodwill2022-08-28SC742693core:IntangibleAssetsOtherThanGoodwill2022-08-28SC742693core:ListedExchangeTraded2022-08-28SC742693core:UnlistedNon-exchangeTraded2022-08-28SC742693core:LandBuildings2022-08-292023-08-31SC742693core:PlantMachinery2022-08-292023-08-31SC742693core:Vehicles2022-08-292023-08-31SC742693core:FurnitureFittings2022-08-292023-08-31SC742693core:OfficeEquipment2022-08-292023-08-31SC742693core:NetGoodwill2022-08-292023-08-31SC742693core:IntangibleAssetsOtherThanGoodwill2022-08-292023-08-31SC742693core:ListedExchangeTraded2022-08-292023-08-31SC742693core:UnlistedNon-exchangeTraded2022-08-292023-08-31SC742693core:MoreThanFiveYears2022-08-292023-08-31SC742693core:Non-currentFinancialInstruments2023-08-31SC742693core:Non-currentFinancialInstruments2022-08-28SC742693dpl:CostSales2022-08-292023-08-31SC742693dpl:DistributionCosts2022-08-292023-08-31SC742693core:LandBuildings2022-08-292023-08-31SC742693core:PlantMachinery2022-08-292023-08-31SC742693core:Vehicles2022-08-292023-08-31SC742693core:FurnitureFittings2022-08-292023-08-31SC742693core:OfficeEquipment2022-08-292023-08-31SC742693dpl:AdministrativeExpenses2022-08-292023-08-31SC742693core:NetGoodwill2022-08-292023-08-31SC742693core:IntangibleAssetsOtherThanGoodwill2022-08-292023-08-31SC742693dpl:GroupUndertakings2022-08-292023-08-31SC742693dpl:ParticipatingInterests2022-08-292023-08-31SC742693dpl:GroupUndertakingscore:ListedExchangeTraded2022-08-292023-08-31SC742693core:ListedExchangeTraded2022-08-292023-08-31SC742693dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-08-292023-08-31SC742693core:UnlistedNon-exchangeTraded2022-08-292023-08-31SC742693dpl:CostSales2022-08-282022-08-28SC742693dpl:DistributionCosts2022-08-282022-08-28SC742693core:LandBuildings2022-08-282022-08-28SC742693core:PlantMachinery2022-08-282022-08-28SC742693core:Vehicles2022-08-282022-08-28SC742693core:FurnitureFittings2022-08-282022-08-28SC742693core:OfficeEquipment2022-08-282022-08-28SC742693dpl:AdministrativeExpenses2022-08-282022-08-28SC742693core:NetGoodwill2022-08-282022-08-28SC742693core:IntangibleAssetsOtherThanGoodwill2022-08-282022-08-28SC742693dpl:GroupUndertakings2022-08-282022-08-28SC742693dpl:ParticipatingInterests2022-08-282022-08-28SC742693dpl:GroupUndertakingscore:ListedExchangeTraded2022-08-282022-08-28SC742693core:ListedExchangeTraded2022-08-282022-08-28SC742693dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-08-282022-08-28SC742693core:UnlistedNon-exchangeTraded2022-08-282022-08-28SC742693core:NetGoodwill2023-08-31SC742693core:IntangibleAssetsOtherThanGoodwill2023-08-31SC742693core:LandBuildings2023-08-31SC742693core:PlantMachinery2023-08-31SC742693core:Vehicles2023-08-31SC742693core:FurnitureFittings2023-08-31SC742693core:OfficeEquipment2023-08-31SC742693core:AfterOneYear2023-08-31SC742693core:WithinOneYear2023-08-31SC742693core:ListedExchangeTraded2023-08-31SC742693core:UnlistedNon-exchangeTraded2023-08-31SC742693core:ShareCapital2023-08-31SC742693core:SharePremium2023-08-31SC742693core:RevaluationReserve2023-08-31SC742693core:OtherReservesSubtotal2023-08-31SC742693core:RetainedEarningsAccumulatedLosses2023-08-31SC742693core:NetGoodwill2022-08-28SC742693core:IntangibleAssetsOtherThanGoodwill2022-08-28SC742693core:LandBuildings2022-08-28SC742693core:PlantMachinery2022-08-28SC742693core:Vehicles2022-08-28SC742693core:FurnitureFittings2022-08-28SC742693core:OfficeEquipment2022-08-28SC742693core:AfterOneYear2022-08-28SC742693core:WithinOneYear2022-08-28SC742693core:ListedExchangeTraded2022-08-28SC742693core:UnlistedNon-exchangeTraded2022-08-28SC742693core:ShareCapital2022-08-28SC742693core:SharePremium2022-08-28SC742693core:RevaluationReserve2022-08-28SC742693core:OtherReservesSubtotal2022-08-28SC742693core:RetainedEarningsAccumulatedLosses2022-08-28SC742693core:NetGoodwill2022-08-28SC742693core:IntangibleAssetsOtherThanGoodwill2022-08-28SC742693core:LandBuildings2022-08-28SC742693core:PlantMachinery2022-08-28SC742693core:Vehicles2022-08-28SC742693core:FurnitureFittings2022-08-28SC742693core:OfficeEquipment2022-08-28SC742693core:AfterOneYear2022-08-28SC742693core:WithinOneYear2022-08-28SC742693core:ListedExchangeTraded2022-08-28SC742693core:UnlistedNon-exchangeTraded2022-08-28SC742693core:ShareCapital2022-08-28SC742693core:SharePremium2022-08-28SC742693core:RevaluationReserve2022-08-28SC742693core:OtherReservesSubtotal2022-08-28SC742693core:RetainedEarningsAccumulatedLosses2022-08-28SC742693core:AfterOneYear2022-08-292023-08-31SC742693core:WithinOneYear2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:CostValuation2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-08-292023-08-31SC742693core:Non-currentFinancialInstrumentscore:CostValuation2023-08-31SC742693core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-31SC742693core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-31SC742693core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-31SC742693core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-31SC742693core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-31SC742693core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-31SC742693core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-31SC742693core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-31SC742693core:Non-currentFinancialInstrumentscore:CostValuation2022-08-28SC742693core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-08-28SC742693core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-08-28SC742693core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-08-28SC742693core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-08-28SC742693core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-08-28SC742693core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-08-28SC742693core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-08-28SC742693core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-08-28SC742693bus:Director12022-08-292023-08-31

GLASGOW LIVER CLINIC LTD

Registered Number
SC742693
(Scotland)

Unaudited Financial Statements for the Period ended
31 August 2023

GLASGOW LIVER CLINIC LTD
Company Information
for the period from 29 August 2022 to 31 August 2023

Director

HEYDTMANN, Mathis, Dr

Registered Address

6 Miller Road
Ayr
KA7 2AY

Registered Number

SC742693 (Scotland)
GLASGOW LIVER CLINIC LTD
Balance Sheet as at
31 August 2023

Notes

2023

£

£

Fixed assets
Tangible assets41,371
1,371
Current assets
Debtors58,399
Cash at bank and on hand21,326
29,725
Creditors amounts falling due within one year6(8,424)
Net current assets (liabilities)21,301
Total assets less current liabilities22,672
Provisions for liabilities(261)
Net assets22,411
Capital and reserves
Called up share capital100
Profit and loss account22,311
Shareholders' funds22,411
The financial statements were approved and authorised for issue by the Director on 15 May 2024, and are signed on its behalf by:
HEYDTMANN, Mathis, Dr
Director
Registered Company No. SC742693
GLASGOW LIVER CLINIC LTD
Notes to the Financial Statements
for the period ended 31 August 2023

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Judgements and key sources of estimation uncertainty
In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. These critical accounting judgements and estimations are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. The critical judgements made by management that have a significant effect on the amounts recognised in the financial statements are described below.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Office Equipment3
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at transaction price and measured at amortised cost using the effective interest method. Where investments in non-derivative financial instruments are publicly traded, or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value through profit and loss. All other investments are subsequently measured at cost less impairment. Financial assets which are measured at cost or amortised cost are reviewed for objective evidence of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. All equity instruments, regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

2023
Average number of employees during the year0
3.Deferred tax
Increases in the UK Corporation tax rate from 19% to 25% (19% effective from 1 April 2017, and 25% effective from 1 April 2023) have been substantively enacted. This will impact the company's future tax charge accordingly. The value of the deferred tax assets at the balance sheet date has been calculated using the applicable rate when the asset is expected to be realised.
4.Tangible fixed assets

Total

£
Cost or valuation
Additions2,047
At 31 August 232,047
Depreciation and impairment
Charge for year676
At 31 August 23675
Net book value
At 31 August 231,371
At 28 August 22-
5.Debtors: amounts due within one year

2023

£
Other debtors8,399
Total8,399
6.Creditors: amounts due within one year

2023

£
Taxation and social security4,960
Accrued liabilities and deferred income3,464
Total8,424
7.Share capital
100 Ordinary Shares of £1